Launch of Lilium one^® in the Japanese market

2023/3/1

Lilium Otsuka launched Lilium one^® which is an innovative palm-sized Ultrasonic Diagnostic Device for the Bladder (Medical device certification number: 303ADBZX00050000) in the Japanese market on March 1, 2023.

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara) is the exclusive medical device distributor in Japan, and the product can be handled by medical institutions nationwide.

Until now, Lilium Otsuka has specialized in the development of technology for urine volume measurement using A-mode ultrasound, and the successful development of Lilium one^® has dramatically improved the operability of the product.

We are convinced that this product will increase its maturity as a product that meets the needs of users and will be positioned as a technology that embodies a disruptive innovation^* in residual urine measurement in the global market.

Lilium Otsuka will continue to develop unique products that only Otsuka can offer in order to help people around the world become more self-reliant in urinating. We will continue to do so in order to contribute to the health of people around the world, consistent with the Otsuka group's corporate philosophy of Otsuka-people creating new products for better health worldwide.

*Disruptive innovation is a business theory developed by Clayton M. Christensen (1952-2020) and others that describes an innovation that goes to the bottom of an existing market and provides a product that matches the needs of users, ultimately replacing an established company or product as the market leader. For further reference: Clayton M. Christensen, et al, Journal of Management Studies, Vol 55, Issue 7, pp. 1025-1322 (2018).